The involvement of sphingolipids in chronic obstructive pulmonary diseases

Research output: Chapter in Book/Report/Conference proceedingChapter

16 Citations (Scopus)

Abstract

Chronic obstructive pulmonary disease (COPD) includes a spectrum of conditions that have in common varying degrees of airflow obstruction, such as chronic bronchitis and emphysema. There is an increasing evidence of involvement of sphingolipids as key molecular mediators or biomarkers of disease in emphysema, chronic bronchitis, and more recently in asthma, another disease characterized by (reversible) airflow obstruction. Given the recognized central role of oxidative stress and inflammatory stimuli along with involvement of immune responses, apoptosis, and tissue remodeling in the development of chronic obstructive lung diseases, it is not surprising that sphingolipids have been shown to play important role in their pathobiology. In particular the pro-apoptotic effects of ceramide were suspected as events in the lung destruction that occurs as a result of apoptotic loss of structural cells comprising the alveolar walls, such as microvascular endothelial cells and alveolar epithelial cells. In addition, the role of ceramide was investigated in models of larger airway epithelial cell stress responses to cigarette smoke, in the context of ensuing airway remodeling and inflammation. This chapter discusses current evidence of sphingolipid perturbations in experimental models of COPD and relevant links to human disease based on translational and epidemiological data.

Original languageEnglish
Title of host publicationHandbook of Experimental Pharmacology
Pages247-264
Number of pages18
Volume216
DOIs
StatePublished - 2013

Publication series

NameHandbook of Experimental Pharmacology
Volume216
ISSN (Print)01712004
ISSN (Electronic)18650325

Fingerprint

Pulmonary diseases
Sphingolipids
Chronic Obstructive Pulmonary Disease
Alveolar Epithelial Cells
Ceramides
Chronic Bronchitis
Emphysema
Airway Remodeling
Oxidative stress
Endothelial cells
Biomarkers
Smoke
Tobacco Products
Oxidative Stress
Theoretical Models
Asthma
Endothelial Cells
Epithelial Cells
Tissue
Apoptosis

Keywords

  • Airflow obstruction
  • Alveolar macrophage
  • Apoptosis
  • Asthma
  • Autophagy
  • Ceramide
  • Cftr
  • Chronic bronchitis
  • Cigarette smoking
  • Copd
  • De novo sphingolipid synthesis
  • Emphysema
  • Endothelial cells
  • Epithelial cells
  • Human
  • Inflammation
  • Lung
  • Mouse
  • Senescence
  • Sphingolipids
  • Sphingomyelinase

ASJC Scopus subject areas

  • Pharmacology, Toxicology and Pharmaceutics(all)
  • Biochemistry

Cite this

Petrache, I., & Petrusca, D. (2013). The involvement of sphingolipids in chronic obstructive pulmonary diseases. In Handbook of Experimental Pharmacology (Vol. 216, pp. 247-264). (Handbook of Experimental Pharmacology; Vol. 216). https://doi.org/10.1007/978-3-7091-1511-4-12

The involvement of sphingolipids in chronic obstructive pulmonary diseases. / Petrache, Irina; Petrusca, Daniela.

Handbook of Experimental Pharmacology. Vol. 216 2013. p. 247-264 (Handbook of Experimental Pharmacology; Vol. 216).

Research output: Chapter in Book/Report/Conference proceedingChapter

Petrache, I & Petrusca, D 2013, The involvement of sphingolipids in chronic obstructive pulmonary diseases. in Handbook of Experimental Pharmacology. vol. 216, Handbook of Experimental Pharmacology, vol. 216, pp. 247-264. https://doi.org/10.1007/978-3-7091-1511-4-12
Petrache I, Petrusca D. The involvement of sphingolipids in chronic obstructive pulmonary diseases. In Handbook of Experimental Pharmacology. Vol. 216. 2013. p. 247-264. (Handbook of Experimental Pharmacology). https://doi.org/10.1007/978-3-7091-1511-4-12
Petrache, Irina ; Petrusca, Daniela. / The involvement of sphingolipids in chronic obstructive pulmonary diseases. Handbook of Experimental Pharmacology. Vol. 216 2013. pp. 247-264 (Handbook of Experimental Pharmacology).
@inbook{9eea07c6dbf44efc9bd345b6c99c809f,
title = "The involvement of sphingolipids in chronic obstructive pulmonary diseases",
abstract = "Chronic obstructive pulmonary disease (COPD) includes a spectrum of conditions that have in common varying degrees of airflow obstruction, such as chronic bronchitis and emphysema. There is an increasing evidence of involvement of sphingolipids as key molecular mediators or biomarkers of disease in emphysema, chronic bronchitis, and more recently in asthma, another disease characterized by (reversible) airflow obstruction. Given the recognized central role of oxidative stress and inflammatory stimuli along with involvement of immune responses, apoptosis, and tissue remodeling in the development of chronic obstructive lung diseases, it is not surprising that sphingolipids have been shown to play important role in their pathobiology. In particular the pro-apoptotic effects of ceramide were suspected as events in the lung destruction that occurs as a result of apoptotic loss of structural cells comprising the alveolar walls, such as microvascular endothelial cells and alveolar epithelial cells. In addition, the role of ceramide was investigated in models of larger airway epithelial cell stress responses to cigarette smoke, in the context of ensuing airway remodeling and inflammation. This chapter discusses current evidence of sphingolipid perturbations in experimental models of COPD and relevant links to human disease based on translational and epidemiological data.",
keywords = "Airflow obstruction, Alveolar macrophage, Apoptosis, Asthma, Autophagy, Ceramide, Cftr, Chronic bronchitis, Cigarette smoking, Copd, De novo sphingolipid synthesis, Emphysema, Endothelial cells, Epithelial cells, Human, Inflammation, Lung, Mouse, Senescence, Sphingolipids, Sphingomyelinase",
author = "Irina Petrache and Daniela Petrusca",
year = "2013",
doi = "10.1007/978-3-7091-1511-4-12",
language = "English",
isbn = "9783709115107",
volume = "216",
series = "Handbook of Experimental Pharmacology",
pages = "247--264",
booktitle = "Handbook of Experimental Pharmacology",

}

TY - CHAP

T1 - The involvement of sphingolipids in chronic obstructive pulmonary diseases

AU - Petrache, Irina

AU - Petrusca, Daniela

PY - 2013

Y1 - 2013

N2 - Chronic obstructive pulmonary disease (COPD) includes a spectrum of conditions that have in common varying degrees of airflow obstruction, such as chronic bronchitis and emphysema. There is an increasing evidence of involvement of sphingolipids as key molecular mediators or biomarkers of disease in emphysema, chronic bronchitis, and more recently in asthma, another disease characterized by (reversible) airflow obstruction. Given the recognized central role of oxidative stress and inflammatory stimuli along with involvement of immune responses, apoptosis, and tissue remodeling in the development of chronic obstructive lung diseases, it is not surprising that sphingolipids have been shown to play important role in their pathobiology. In particular the pro-apoptotic effects of ceramide were suspected as events in the lung destruction that occurs as a result of apoptotic loss of structural cells comprising the alveolar walls, such as microvascular endothelial cells and alveolar epithelial cells. In addition, the role of ceramide was investigated in models of larger airway epithelial cell stress responses to cigarette smoke, in the context of ensuing airway remodeling and inflammation. This chapter discusses current evidence of sphingolipid perturbations in experimental models of COPD and relevant links to human disease based on translational and epidemiological data.

AB - Chronic obstructive pulmonary disease (COPD) includes a spectrum of conditions that have in common varying degrees of airflow obstruction, such as chronic bronchitis and emphysema. There is an increasing evidence of involvement of sphingolipids as key molecular mediators or biomarkers of disease in emphysema, chronic bronchitis, and more recently in asthma, another disease characterized by (reversible) airflow obstruction. Given the recognized central role of oxidative stress and inflammatory stimuli along with involvement of immune responses, apoptosis, and tissue remodeling in the development of chronic obstructive lung diseases, it is not surprising that sphingolipids have been shown to play important role in their pathobiology. In particular the pro-apoptotic effects of ceramide were suspected as events in the lung destruction that occurs as a result of apoptotic loss of structural cells comprising the alveolar walls, such as microvascular endothelial cells and alveolar epithelial cells. In addition, the role of ceramide was investigated in models of larger airway epithelial cell stress responses to cigarette smoke, in the context of ensuing airway remodeling and inflammation. This chapter discusses current evidence of sphingolipid perturbations in experimental models of COPD and relevant links to human disease based on translational and epidemiological data.

KW - Airflow obstruction

KW - Alveolar macrophage

KW - Apoptosis

KW - Asthma

KW - Autophagy

KW - Ceramide

KW - Cftr

KW - Chronic bronchitis

KW - Cigarette smoking

KW - Copd

KW - De novo sphingolipid synthesis

KW - Emphysema

KW - Endothelial cells

KW - Epithelial cells

KW - Human

KW - Inflammation

KW - Lung

KW - Mouse

KW - Senescence

KW - Sphingolipids

KW - Sphingomyelinase

UR - http://www.scopus.com/inward/record.url?scp=84880540714&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84880540714&partnerID=8YFLogxK

U2 - 10.1007/978-3-7091-1511-4-12

DO - 10.1007/978-3-7091-1511-4-12

M3 - Chapter

SN - 9783709115107

VL - 216

T3 - Handbook of Experimental Pharmacology

SP - 247

EP - 264

BT - Handbook of Experimental Pharmacology

ER -